Peripheral and central sites of action of GABA-B agonists to inhibit the cough reflex in the cat and guinea pig.
1. The GABA-B receptor agonists baclofen and 3-aminopropylphosphinic acid (3-APPi) have antitussive activity in the cat and guinea pig. The purpose of this study was to investigate the sites of action of these GABA-B receptor agonists to inhibit the cough reflex. 2. Single intracerebroventricular (i.c.v.) cannulas were placed in the lateral ventricles of anaesthetized guinea pigs. Approximately 1 week later, the animals were exposed to aerosols of capsaicin (0.3 mM) to elicit coughing. Coughs were detected with a microphone and counted. 3. Cough was produced in anaesthetized cats by mechanical stimulation of the intrathoracic trachea and was recorded from electromyograms of respiratory muscle activity. Cannulas were placed for intravenous (i.v.) or, in separate groups of animals, intravertebral arterial (i.a.) administration of baclofen, 3-APPi, the centrally active antitussive drug codeine or the peripherally active antitussive drug BW443c. Dose-response relationships for i.v. and i.a. administration of each drug were generated to determine a ratio of i.v. ED50 to i.a. ED50, known as the effective dose ratio (EDR). The EDR will be 20 or greater for a centrally acting drug. 4. In the guinea pig, baclofen (3 mg kg-1, s.c.) and 3-APPi (10 mg kg-1, s.c.) inhibited capsaicin-induced cough by 50% and 35% respectively. The antitussive activity of baclofen was completely blocked by i.c.v. administration of the GABA-B receptor antagonist CGP 35348 (10 micrograms). Conversely, the antitussive effect of 3-APPi was unaffected by i.c.v. CGP 35348. However, systemic administration of CGP 35348 (30 mg kg-1, s.c.) completely blocked the antitussive activity of 3-APPi (10 mg kg-1, s.c.). In separate experiments baclofen alone (1 microg, i.c.v.) inhibited capsaicin-induced cough by 78%. 3-APPi (10 and 100 microg, i.c.v.) had no effect on capsaicin-induced cough in the guinea pig.5. In the cat, potencies (ED50) of the standards and GABA-B agonists by the i.v. route were: codeine(0.34 mg kg-1), BW443C (0.17 mg kg-1), baclofen (0.63 mg kg-1) and 3-APPi (2.3 mg kg-1). Potencies of these drugs by the i.a. route were: codeine, 0.013 mg kg-1; BW443C, 0.06mg kg-1; baclofen,0.016mg kg-1; and 3-APPi, 0.87 mg kg-1. The EDRs for each drug were: codeine, 26; BW443C, 3;baclofen, 39; and 3-APPi, 3.6 We conclude that in both the cat and guinea pig baclofen inhibits cough by a central site of action,while 3-APPi inhibits cough by a peripheral site of action.
Bolser
D C
DC
Schering-Plough Research Institute, Kenilworth, NJ 07033.
DeGennaro
F C
FC
O'Reilly
S
S
Chapman
R W
RW
Kreutner
W
W
Egan
R W
RW
Hey
J A
JA
D000818:Animals; D000996:Antitussive Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology; D001418:Baclofen / Q000037:antagonists & inhibitors / Q000494:pharmacology; D002211:Capsaicin; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects / Q000502:physiology*; D003061:Codeine / Q000494:pharmacology; D003371:Cough / Q000139:chemically induced / Q000503:physiopathology*; D018755:GABA Agonists / Q000494:pharmacology; D058786:GABA-B Receptor Agonists; D058788:GABA-B Receptor Antagonists; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007276:Injections, Intraventricular; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D017933:Peripheral Nervous System / Q000187:drug effects / Q000502:physiology*
D000996:Antitussive Agents; D018755:GABA Agonists; D058786:GABA-B Receptor Agonists; D058788:GABA-B Receptor Antagonists; D009842:Oligopeptides; D009943:Organophosphorus Compounds; C061388:3-aminopropylphosphinic acid; C066430:CGP 35348; C055303:BW 443C; D001418:Baclofen; D002211:Capsaicin; D003061:Codeine